Clinical Trials
1,331 trialsNCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT06058377 2026-05-27
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06492616 2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT07578116 2026-05-27
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT00310180 2026-05-26
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01272037 2026-05-26
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07237256 2026-05-26
NoLEEta
UNICANCER
Phase 3 Recruiting
NCT07461454 2026-05-26
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT04961996 2026-05-22
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05417516 2026-05-22
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Ontario Clinical Oncology Group (OCOG)
Phase 3 Recruiting
NCT06312176 2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06393374 2026-05-22
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06841354 2026-05-22
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06966700 2026-05-22
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07060807 2026-05-22
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07173751 2026-05-22
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
BioNTech SE
Phase 3 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07349069 2026-05-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT07492641 2026-05-22
KANDELA-302
BeOne Medicines
Phase 3 Recruiting
NCT07541079 2026-05-22
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Genentech, Inc.
Phase 3 Not yet recruiting
NCT03425838 2026-05-20
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Borstkanker Onderzoek Groep
Phase 3 Active not recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT04546009 2026-05-19
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06760637 2026-05-19
FourLight-3
Pfizer
Phase 3 Active not recruiting
NCT00376597 2026-05-18
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT07593846 2026-05-18
DETE-BR
West China Hospital
Phase 3 Not yet recruiting
NCT02954874 2026-05-15
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04622319 2026-05-15
DESTINY-Breast05
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05374512 2026-05-15
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT05512364 2026-05-15
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT07085767 2026-05-15
OPERA-02
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07357298 2026-05-15
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 3 Recruiting
NCT07590505 2026-05-15
ULTIMO
Cancer Research Antwerp
Phase 3 Completed
NCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06377852 2026-05-13
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT07391774 2026-05-13
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
National Cancer Institute (NCI)
Phase 3 Not yet recruiting
NCT00433511 2026-05-12
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02445391 2026-05-12
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT03488693 2026-05-12
TAILOR RT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04739761 2026-05-12
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT07205822 2026-05-12
TB06
AstraZeneca
Phase 3 Recruiting
NCT04055493 2026-05-11
ADAPTcycle
West German Study Group
Phase 3 Active not recruiting
NCT04251533 2026-05-11
EPIK-B3
Novartis
Phase 3 Terminated
NCT05379153 2026-05-11
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05347134 2026-05-08
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05774951 2026-05-08
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting